Coffee

Research summary

• Coffee is one of the most extensively studied beverages in nutritional epidemiology, and the evidence points toward modest benefit rather than harm at typical intake levels.
• An umbrella review of 201 meta-analyses of observational studies found coffee consumption more often associated with benefit than harm, with the largest risk reductions at 3-4 cups per day, including 17% lower all-cause mortality and 19% lower cardiovascular mortality versus none.
• A separate meta-analysis of 40 studies and over 3.8 million participants found the lowest mortality risk at roughly 2-4 cups daily, with the inverse association holding across age, smoking status and region.
• Dose-response meta-analyses of cardiovascular disease specifically found the lowest risk at 3-5 cups per day and no evidence of elevated risk even at high intake, and a meta-analysis restricted to hypertensive individuals found no association between habitual coffee consumption and increased cardiovascular risk, despite caffeine's acute, short-lived effect of raising blood pressure.
• Newer cohort work adds an important nuance: the mortality benefit is weaker or absent when coffee is loaded with added sugar or saturated fat, with one large NHANES analysis finding benefit was largely restricted to black coffee or coffee with little added sugar/fat.
• A multicenter cohort in atrial fibrillation patients also found no evidence that coffee raises cardiovascular risk in that population, addressing a common clinical concern.
• All of this evidence is observational — there is no long-term mortality RCT for coffee, and reverse causation (sick people quitting coffee) remains a standing methodological concern — but the consistency across countries, decades and multiple health endpoints is considerable.